Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
WESTLAKE VILLAGE, Calif., May 02, 2018 -- MannKind Corporation (Nasdaq:MNKD) will release its 2018 first quarter financial results on Wednesday, May 9, 2018 and its management will host a conference call to discuss the financial results and other Company developments at 5:00 PM (Eastern Time) on May 9, 2018.
Presenting from the Company will be its Chief Executive Officer, Michael Castagna, Chief Financial Officer, Steven Binder, Chief Commercial Officer, Pat McCauley and Chief Medical Officer, David Kendall.
To view and listen to the earnings call webcast live via the Internet, visit the Company's website at www.mannkindcorp.com and click on the “Q1 2018 MannKind Earnings Conference Call” link in the Webcasts section of News & Events. To participate in the live call by telephone, please dial (800) 289-0438 toll-free or (323) 794-2423 toll/international and use the conference passcode: 3321662.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (844) 512-2921 toll-free or (412) 317-6671 toll/international and use the replay passcode: 3321662. A replay will also be available on MannKind's website for 14 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) inhalation powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
[email protected]
